Higher complete reperfusion rate seen with tenecteplase vs. alteplase in single-center study of stroke with LVO
New interventions and medications expand options, extend treatment window
Advice on why and how based on Cleveland Clinic’s recent enterprise-wide transition
$2M NIH grant will help see if dual-action agent lengthens treatment window
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Door-to-needle time improved by 26 percent from 2014 to 2017
ATTRACT trial finds no reduced risk versus anticoagulation alone following DVT
Finding the balance